CD177 and amyotrophic lateral sclerosis: Our study is the first report of the beneficial effects of treatment with sRAGE, which sequesters RAGE ligands and prevents their interaction with and activation of the cell surface receptor, in delaying the onset and progression of a neurodegenerative disease in the SOD1 transgenic mouse model of ALS.